Cardiovascular effects have been recorded with bradycardia and sinus arrhythmia being consistently recorded in 68 % of patients treated with mefloquine ( in one hospital-based study ).
12.
Activity in this range is associated with the respiratory sinus arrhythmia ( RSA ), a vagally mediated modulation of heart rate such that it increases during inspiration and decreases during expiration.
13.
It is a 30-amino acid non-C-terminally amidated peptide that potently stimulates growth hormone secretion, inhibits cardiac vagal slowing of heart rate, abolishes sinus arrhythmia, and inhibits postprandial gastrointestinal motility.
14.
This theory decomposes heart rate variability based on frequency domain characteristics with an emphasis on respiratory sinus arrhythmia and its transmission by a neural pathway that is distinct from other components of HRV . There is anatomic and physiological evidence for a polyvagal control of the heart.
